SALT LAKE CITY – November 05, 2026 -- Co-Diagnostics, Inc. (Nasdaq: CODX) will release its third quarter 2026 financial results on Tuesday, November 10, after the market close, two days ahead of the previously announced date of Thursday, November 12.
Co-Diagnostics schedules a 4:30 p.m. ET call on the new date
The molecular diagnostics company will host a conference call and webcast at 4:30 p.m. ET on November 10 to discuss the results. Investors can join the webcast through the Events & Webcasts page of the company's investor relations site or dial in by toll-free or toll number. A recording will be posted on the company's website for those who cannot attend live.
Co-Dx PCR platform remains pending regulatory review
Co-Diagnostics designs tests around the detection and analysis of nucleic acid molecules, DNA or RNA. Its Co-Dx PCR at-home and point-of-care platform is subject to regulatory review and is not currently for sale. The company also applies its proprietary technology to identify genetic markers for uses beyond infectious disease.